特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
963749

神経変性疾患治療薬の世界市場 (2019-2030年):製品・機序・投与経路・適応症・地域/国別

Global Neurodegenerative Disorder Therapeutics Market: Focus on Product, Mechanism, Route of Administration, Indication, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 327 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.60円
神経変性疾患治療薬の世界市場 (2019-2030年):製品・機序・投与経路・適応症・地域/国別
出版日: 2020年10月08日
発行: BIS Research Inc.
ページ情報: 英文 327 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の神経変性疾患治療薬の市場規模は予測期間中7.21%のCAGRで推移し、2030年には981億6000万米ドルの規模に成長すると予測されています。老齢人口の増加、神経変性疾患を含む慢性疾患の発生率の増加、免疫疾患治療におけるアンメットニーズ、R&Dへの大規模な資金投入などの要因が同市場の成長を推進しています。

当レポートでは、世界の神経変性疾患治療薬の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制の枠組み、価格設定・償還シナリオ、パイプラインの動向、市場規模の推移・予測、製品タイプ・薬剤クラス・適応症・投与経路・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 技術の定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

  • 神経変性疾患治療薬とその臨床的重要性
  • 神経変性疾患治療薬の開発と商品化の情勢
  • 世界の神経変性疾患治療薬市場と成長の可能性
  • 価格設定・償還シナリオ
  • 特許の有効期限とバイオシミラーの参入が市場に与える影響
  • COVID-19の影響

第5章 神経変性疾患治療薬の疫学

第6章 特許情勢

第7章 市場力学

  • 概要
  • 影響分析
  • 成長推進因子
  • 成長抑制因子
  • 市場機会

第8章 産業考察

  • 概要
  • 規制シナリオ
  • 法的要件・枠組み:米国
  • 法的要件・枠組み:欧州
  • 法的要件・枠組み:アジア太平洋
  • 迅速承認
  • 規制機関・コンソーシアムの役割
  • 規制ガイドライン
  • 規制上の課題
  • 償還・市場アクセス

第9章 市場分析・予測:製品タイプ別

  • 上市済み薬
    • 多発性硬化症
    • てんかん
    • アルツハイマー病
    • パーキンソン病
    • 脊髄性筋萎縮症(SMA)
    • ハンチントン病
  • パイプライン薬
    • 多発性硬化症
    • アルツハイマー病
    • パーキンソン病
    • ハンチントン病

第10章 市場分析・予測:薬剤クラス別

  • 免疫調節剤
  • インターフェロン
  • ドーパミン作動薬
  • デカルボキシラーゼ阻害剤
  • その他

第11章 市場分析・予測:適応症別

  • 多発性硬化症
  • てんかん
  • 脊髄性筋萎縮症(SMA)
  • アルツハイマー病
  • パーキンソン病
  • ハンチントン病
  • その他の神経障害

第12章 市場分析・予測:投与経路別

  • 経口
  • 注射
  • 経腸
  • 経皮
  • その他

第13章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • 中南米
    • ブラジル
    • メキシコ
    • その他
  • その他の地域

第14章 競合情勢

  • 主な展開・戦略
  • 市場シェア分析

第15章 企業プロファイル

  • AbbVie Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma SA.
図表

List of Figures

  • Figure 1: Global Total Burden of Diseases by Cause
  • Figure 2: Global Geriatric Population by Age
  • Figure 3: Global Neurodegenerative Disorder Therapeutics Market
  • Figure 4: Impact Analysis
  • Figure 5: Share of Key Developments and Strategies, June 2015-June 2020
  • Figure 6: Global Neurodegenerative Disorder Therapeutics Market (by Drug Class), 2019 and 2030
  • Figure 7: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2019 and 2030
  • Figure 8: Global Neurodegenerative Disorder Therapeutics Market (by Route of Administraton), 2019 and 2030
  • Figure 9: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
  • Figure 2.1: Global Neurodegenerative Disorder Therapeutics Market Segmentation
  • Figure 3.1: Global Neurodegenerative Disorder Therapeutic Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Neurodegenerative Disorder Therapeutics Clinical Trial Landscape
  • Figure 4.2: Global Neurodegenerative Disorder Market 2019-2030
  • Figure 4.3: Patent Expiry of Neurodegenerative Disorder Therapies
  • Figure 4.4: Most Impacted Practices in the Treatment of Neurodegenerative Disorders
  • Figure 5.1: Prevalence of Neurodegenerative Disorders in the U.S. (Total Population)
  • Figure 5.2: Prevalence of Alzheimer's Disease in the U.S. (Total Population)
  • Figure 5.3: Prevalence of Epilepsy in the U.S. (Total Population)
  • Figure 5.4: Prevalence of Parkinson's Disease in the U.S. (Total Population)
  • Figure 5.5: Prevalence of Multiple Sclerosis in the U.S. (Total Population)
  • Figure 5.6: Prevalence of Spinal Muscular Atrophy (SMA) in the U.S. (Total Population)
  • Figure 5.7: Prevalence of Huntington's Disease in the U.S. (Total Population)
  • Figure 5.8: Target Population of Epilepsy in the U.S.
  • Figure 5.9: Target Population of Alzheimer's Disease in the U.S.
  • Figure 5.10: Target Population of Multiple Sclerosis in the U.S.
  • Figure 5.11: Target Population of Parkinson's Disease in the U.S.
  • Figure 5.12: Target Population of Huntington's Disease in the U.S.
  • Figure 6.1: Number of Patents Filed, Neurodegenerative Disorder Therapeutics/Drugs, January 2015-December 2019
  • Figure 6.2: Number of Patents Filed, Multiple Sclerosis Therapeutics/Drugs, January 2015-December 2019
  • Figure 6.3: Number of Patents Filed, Alzheimer's Disease Therapeutics/Drugs, January 2015-December 2019
  • Figure 6.4: Percentage of Patents Filed, By Patent Office, January 2015-December 2019
  • Figure 7.1: Impact Analysis
  • Figure 7.2: Global Total Burden of Diseases by Cause
  • Figure 7.3: Global Geriatric Population by Age
  • Figure 8.1: Steps for Obtaining Marketing Authorization
  • Figure 8.2: USFDA Review Timeline
  • Figure 8.3: EMA Review Timeline
  • Figure 9.1: Global Neurodegenerative Disorder Therapeutics Market (Tecfidera - Product Revenue), 2019-2030
  • Figure 9.2: Global Neurodegenerative Disorder Therapeutics Market (Ocrevus - Product Revenue), 2019-2030
  • Figure 9.3: Global Neurodegenerative Disorder Therapeutics Market (Gilenya - Product Revenue), 2019-2030
  • Figure 9.4: Global Neurodegenerative Disorder Therapeutics Market (Aubagio - Product Revenue), 2019-2030
  • Figure 9.5: Global Neurodegenerative Disorder Therapeutics Market (Interferon (Avonex and Plegridy) - Product Revenue), 2019-2030
  • Figure 9.6: Global Neurodegenerative Disorder Therapeutics Market (Tysabri - Product Revenue), 2019-2030
  • Figure 9.7: Global Neurodegenerative Disorder Therapeutics Market (Rebif - Product Revenue), 2019-2030
  • Figure 9.8: Global Neurodegenerative Disorder Therapeutics Market (Copaxone - Product Revenue), 2019-2030
  • Figure 9.9: Global Neurodegenerative Disorder Therapeutics Market (Betaseron - Product Revenue), 2019-2030
  • Figure 9.10: Global Neurodegenerative Disorder Therapeutics Market (Lemtrada - Product Revenue), 2019-2030
  • Figure 9.11: Global Neurodegenerative Disorder Therapeutics Market (Mavenclad - Product Revenue), 2019-2030
  • Figure 9.12: Global Neurodegenerative Disorder Therapeutics Market (Fampyra - Product Revenue), 2019-2030
  • Figure 9.13: Global Neurodegenerative Disorder Therapeutics Market (Ampyra - Product Revenue), 2019-2030
  • Figure 9.14: Global Neurodegenerative Disorder Therapeutics Market (Mayzent - Product Revenue), 2019-2030
  • Figure 9.15: Global Neurodegenerative Disorder Therapeutics Market (Vumerity - Product Revenue), 2019-2030
  • Figure 9.16: Global Neurodegenerative Disorder Therapeutics Market (Others - Product Revenue), 2019-2030
  • Figure 9.17: Global Neurodegenerative Disorder Therapeutics Market (Lyrica - Product Revenue), 2019-2030
  • Figure 9.18: Global Neurodegenerative Disorder Therapeutics Market (Vimpat - Product Revenue), 2019-2030
  • Figure 9.19: Global Neurodegenerative Disorder Therapeutics Market (Onfi - Product Revenue), 2019-2030
  • Figure 9.20: Global Neurodegenerative Disorder Therapeutics Market (Keppra - Product Revenue), 2019-2030
  • Figure 9.21: Global Neurodegenerative Disorder Therapeutics Market (Sabril - Product Revenue), 2019-2030
  • Figure 9.22: Global Neurodegenerative Disorder Therapeutics Market (Briviact - Product Revenue), 2019-2030
  • Figure 9.23: Global Neurodegenerative Disorder Therapeutics Market (Fycompa - Product Revenue), 2019-2030
  • Figure 9.24: Global Neurodegenerative Disorder Therapeutics Market (Banzel - Product Revenue), 2019-2030
  • Figure 9.25: Global Neurodegenerative Disorder Therapeutics Market (Others - Product Revenue), 2019-2030
  • Figure 9.26: Global Neurodegenerative Disorder Therapeutics Market (Ebixa - Product Revenue), 2019-2030
  • Figure 9.27: Global Neurodegenerative Disorder Therapeutics Market (Namenda XR - Product Revenue), 2019-2030
  • Figure 9.28: Global Neurodegenerative Disorder Therapeutics Market (Namzaric - Product Revenue), 2019-2030
  • Figure 9.29: Global Neurodegenerative Disorder Therapeutics Market (Galantamine - Product Revenue), 2019-2030
  • Figure 9.30: Global Neurodegenerative Disorder Therapeutics Market (Others - Product Revenue), 2019-2030
  • Figure 9.31: Global Neurodegenerative Disorder Therapeutics Market (Azilect - Product Revenue), 2019-2030
  • Figure 9.32: Global Neurodegenerative Disorder Therapeutics Market (Neupro - Product Revenue), 2019-2030
  • Figure 9.33: Global Neurodegenerative Disorder Therapeutics Market (Madopar - Product Revenue), 2019-2030
  • Figure 9.34: Global Neurodegenerative Disorder Therapeutics Market (Duopa - Product Revenue), 2019-2030
  • Figure 9.35: Global Neurodegenerative Disorder Therapeutics Market (Inbrija - Product Revenue), 2019-2030
  • Figure 9.36: Global Neurodegenerative Disorder Therapeutics Market (Others - Product Revenue), 2019-2030
  • Figure 9.37: Global Neurodegenerative Disorder Therapeutics Market (Spinraza - Product Revenue), 2019-2030
  • Figure 9.38: Global Neurodegenerative Disorder Therapeutics Market (Zolgensma - Product Revenue), 2019-2030
  • Figure 9.39: Global Neurodegenerative Disorder Therapeutics Market (Others - Product Revenue), 2019-2030
  • Figure 9.40: Global Neurodegenerative Disorder Therapeutics Market (Austedo - Product Revenue),2019-2030
  • Figure 9.41: Global Neurodegenerative Disorder Therapeutics Market (Xenazine - Product Revenue),2019-2030
  • Figure 9.42: Global Neurodegenerative Disorder Therapeutics Market (Others - Product Revenue), 2019-2030
  • Figure 9.43: Global Neurodegenerative Disorder Therapeutics Market (Zeposia Expected Launch - 2020), 2019-2030
  • Figure 9.44: Global Neurodegenerative Disorder Therapeutics Market (Ponesimod Expected Launch - 2020), 2019-2030
  • Figure 9.45: Global Neurodegenerative Disorder Therapeutics Market (Ofatumumab Expected Launch 2021), 2019-2030
  • Figure 9.46: Global Neurodegenerative Disorder Therapeutics Market (Ublituximab Expected Launch - 2021), 2019-2030
  • Figure 9.47: Global Neurodegenerative Disorder Therapeutics Market (Ibudilast Expected Launch - 2022), 2019-2030
  • Figure 9.48: Global Neurodegenerative Disorder Therapeutics Market (SAR442168 Expected Launch - 2026), 2019-2030
  • Figure 9.49: Global Neurodegenerative Disorder Therapeutics Market (Tricaprilin Expected Launch - 2023), 2019-2030
  • Figure 9.50: Global Neurodegenerative Disorder Therapeutics Market (Bryostatin-1 Expected Launch - 2025), 2019-2030
  • Figure 9.51: Global Neurodegenerative Disorder Therapeutics Market (AGB101 Expected Launch - 2025), 2019-2030
  • Figure 9.52: Global Neurodegenerative Disorder Therapeutics Market (COR388 Expected Launch - 2023), 2019-2030
  • Figure 9.53: Global Neurodegenerative Disorder Therapeutics Market (TRx0237 Expected Launch - 2024), 2019-2030
  • Figure 9.54: Global Neurodegenerative Disorder Therapeutics Market (Brexpiprazole Expected Launch - 2023), 2019-2030
  • Figure 9.55: Global Neurodegenerative Disorder Therapeutics Market (Semorinemab Expected Launch - 2024), 2019-2030
  • Figure 9.56: Global Neurodegenerative Disorder Therapeutics Market (Aducanumab Expected Launch - 2020), 2019-2030
  • Figure 9.57: Global Neurodegenerative Disorder Therapeutics Market (Eltoprazine Expected Launch - 2020), 2019-2030
  • Figure 9.58: Global Neurodegenerative Disorder Therapeutics Market (Ongentys Expected Launch - 2020), 2019-2030
  • Figure 9.59: Global Neurodegenerative Disorder Therapeutics Market (IPX-066 Expected Launch - 2020), 2019-2030
  • Figure 9.60: Global Neurodegenerative Disorder Therapeutics Market (Xadago Expected Launch - 2020), 2019-2030
  • Figure 9.61: Global Neurodegenerative Disorder Therapeutics Market (Nourianz Expected Launch - 2020), 2019-2030
  • Figure 9.62: Global Neurodegenerative Disorder Therapeutics Market (Opicapone Expected Launch - 2020), 2019-2030
  • Figure 9.63: Global Neurodegenerative Disorder Therapeutics Market (RG6042/IONIS -HTTrx Expected Launch - 2021), 2019-2030
  • Figure 9.64: Global Neurodegenerative Disorder Therapeutics Market (WVE-120101 Expected Launch - 2022), 2019-2030
  • Figure 9.65: Global Neurodegenerative Disorder Therapeutics Market (WVE-120102 Expected Launch - 2022), 2019-2030
  • Figure 10.1: Revenue Contribution of Different Segments, 2019 and 2030
  • Figure 10.2: Global Neurodegenerative Disorder Therapeutics Market (by Immunomodulators), 2019-2030
  • Figure 10.3: Global Neurodegenerative Disorder Therapeutics Market (by Interferons), 2019-2030
  • Figure 10.4: Global Neurodegenerative Disorder Therapeutics Market (by Dopamine agonists), 2019-2030
  • Figure 10.5: Global Neurodegenerative Disorder Therapeutics Market (by Decarboxylase Inhibitors), 2019-2030
  • Figure 10.6: Global Neurodegenerative Disorder Therapeutics Market (by Others), 2019-2030
  • Figure 11.1: Global Neurodegenerative Disorder Therapeutics Market, by Indication
  • Figure 11.2: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2020 and 2030
  • Figure 11.3: Global Neurodegenerative Disorder Therapeutics Market (by Multiple Sclerosis), 2019-2030
  • Figure 11.4: Global Neurodegenerative Disorder Therapeutics Market (by Epilepsy), 2019-2030
  • Figure 11.5: Global Neurodegenerative Disorder Therapeutics Market (by Spinal Muscular Atrophy), 2019-2030
  • Figure 11.6: Global Neurodegenerative Disorder Therapeutics Market (by Alzheimer's disease), 2019-2030
  • Figure 11.7: Global Neurodegenerative Disorder Therapeutics Market (by Parkinson's disease), 2019-2030
  • Figure 11.8: Global Neurodegenerative Disorder Therapeutics Market (by Huntington's disease), 2019-2030
  • Figure 11.9: Global Neurodegenerative Disorder Therapeutics Market (by Other Neurological Disorders), 2019-2030
  • Figure 12.1: Revenue Contribution of Different Segments, 2020 and 2030
  • Figure 12.2: Global Neurodegenerative Disorder Therapeutics Market (by Oral), 2019-2030
  • Figure 12.3: Global Neurodegenerative Disorder Therapeutics Market (by Injectable), 2019-2030
  • Figure 12.4: Global Neurodegenerative Disorder Therapeutics Market (by Enteral), 2019-2030
  • Figure 12.5: Global Neurodegenerative Disorder Therapeutics Market (by Transdermal), 2019-2030
  • Figure 12.6: Global Neurodegenerative Disorder Therapeutics Market (by Other RoA), 2019-2030
  • Figure 13.1: Global Neurodegenerative Disorder Therapeutics Market (by Region)
  • Figure 13.2: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
  • Figure 13.3: North America Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.4: North America: Market Dynamics
  • Figure 13.5: Revenue Contributions of Different Countries in North America, 2019 and 2030
  • Figure 13.6: U.S. Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.7: U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.8: Canada Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.9: Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.10: Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.11: Europe: Market Dynamics
  • Figure 13.12: Revenue Contributions Different Countries in Europe, 2019 and 2030
  • Figure 13.13: Germany Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.14: Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.15: U.K. Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.16: U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.17: France Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.18: France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.19: Italy Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.20: Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.21: Spain Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.22: Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.23: Rest-of-Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.24: RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.25: Asia-Pacific Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.26: APAC: Market Dynamics
  • Figure 13.27: Revenue Contributions Different Countries in Asia-Pacific, 2019 and 2030
  • Figure 13.28: China Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.29: China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.30: Japan Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.31: Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.32: India Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.33: India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.34: South Korea Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.35: South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.36: Australia Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.37: Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.38: RoAPAC Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.39: RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.40: Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.41: Latin America Neurodegenerative Disorder Therapeutics Market (by Country), 2019-2030
  • Figure 13.42: Revenue Contributions Different Countries in Latin America, 2019 and 2030
  • Figure 13.43: Brazil Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.44: Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.45: Mexico Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.46: Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.47: Rest-of-Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
  • Figure 13.48: RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • Figure 13.49: RoW Neurodegenerative disorder therapeutics market, 2019-2030
  • Figure 14.1: Share of Key Developments and Strategies, July 2015 - July 2020
  • Figure 14.2: Regulatory and Legal Developments Share (by Company), July 2015 - July 2020
  • Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company), July 2015 - July 2020
  • Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020
  • Figure 14.5: Market Share Analysis (by Companies), 2018 and 2019
  • Figure 15.1: Total Number of Companies Profiled
  • Figure 15.2: AbbVie Inc.: Overall Product Portfolio
  • Figure 15.3: AbbVie Inc.: Overall Financials, 2017-2019
  • Figure 15.4: AbbVie Inc.: Revenue (by Region), 2017-2019
  • Figure 15.5: AbbVie Inc.: R&D Expenditure, 2017-2019
  • Figure 15.6: AbbVie Inc.: SWOT Analysis
  • Figure 15.7: Bayer AG: Overall Product Portfolio
  • Figure 15.8: Bayer AG: Overall Financials, 2017-2019
  • Figure 15.9: Bayer AG: Revenue (by Segment), 2018-2019
  • Figure 15.10: Bayer AG: Revenue (by Region), 2017-2019
  • Figure 15.11: Bayer AG: R&D Expenditure, 2017-2019
  • Figure 15.12: Bayer AG: SWOT Analysis
  • Figure 15.13: Biogen Inc.: Overall Service Portfolio
  • Figure 15.14: Biogen Inc.: Overall Financials, 2017-2019
  • Figure 15.15: Biogen Inc.: Sales (by Product), 2017-2019
  • Figure 15.16: Biogen Inc.: Sales (by Region), 2017-2019
  • Figure 15.17: Biogen Inc.: R&D Expenditure, 2017-2019
  • Figure 15.18: Biogen Inc.: SWOT Analysis
  • Figure 15.19: Bristol Myers Squibb Company: Overall Product Portfolio
  • Figure 15.20: Bristol Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 15.21: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
  • Figure 15.22: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
  • Figure 15.23: Bristol Myers Squibb Company: SWOT Analysis
  • Figure 15.24: C. H. Boehringer Sohn AG & Co. KG: Overall Product Portfolio
  • Figure 15.25: C. H. Boehringer Sohn AG & Co. KG: Overall Financials, 2017-2019
  • Figure 15.26: C. H. Boehringer Sohn AG & Co. KG: Revenue (by Segment), 2017-2019
  • Figure 15.27: C. H. Boehringer Sohn AG & Co. KG: Revenue (by Region), 2017-2019
  • Figure 15.28: C. H. Boehringer Sohn AG & Co. KG: R&D Expenditure, 2017-2019
  • Figure 15.29: C. H. Boehringer Sohn AG & Co. KG: SWOT Analysis
  • Figure 15.30: Eisai Inc.: Overall Product Portfolio
  • Figure 15.31: Eisai Inc.: Overall Financials, 2017-2019
  • Figure 15.32: Eisai Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.33: Eisai Inc.: Revenue (by Region), 2017-2019
  • Figure 15.34: Eisai Inc.: R&D Expenditure, 2017-2019
  • Figure 15.35: Eisai Inc.: SWOT Analysis
  • Figure 15.36: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 15.37: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 15.38: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 15.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 15.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 15.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 15.42: GlaxoSmithKline plc: Overall Product Portfolio
  • Figure 15.43: GlaxoSmithKline plc: Overall Financials, 2017-2019
  • Figure 15.44: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
  • Figure 15.45: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
  • Figure 15.46: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
  • Figure 15.47: GlaxoSmithKline plc: SWOT Analysis
  • Figure 15.48: H. Lundbeck A/S: Overall Product Portfolio
  • Figure 15.49: H. Lundbeck A/S: Overall Financials, 2017-2019
  • Figure 15.50: H. Lundbeck A/S: Revenue (by Segment), 2017-2019
  • Figure 15.51: H. Lundbeck A/S: Revenue (by Region), 2017-2019
  • Figure 15.52: H. Lundbeck A/S: R&D Expenditure, 2017-2019
  • Figure 15.53: H. Lundbeck A/S: SWOT Analysis
  • Figure 15.54: Merck KGaA: Product Portfolio
  • Figure 15.55: Merck KGaA: Overall Financials, 2017-2019
  • Figure 15.56: Merck KGaA: Revenue (by Segment), 2017-2019
  • Figure 15.57: Merck KGaA: Revenue (by Region), 2017-2019
  • Figure 15.58: Merck KGaA: R&D Expenditure, 2017-2019
  • Figure 15.59: Merck KGaA: SWOT Analysis
  • Figure 15.60: Novartis AG: Overall Financials, 2017-2019
  • Figure 15.61: Novartis AG Net Revenue (by Business Segment), 2017-2019
  • Figure 15.62: Novartis AG: Net Revenue (by Region), 2017-2019
  • Figure 15.63: Novartis AG: R& D Expense, 2017-2019
  • Figure 15.64: Novartis AG: SWOT Analysis
  • Figure 15.65: Pfizer Inc.: Overall Product Portfolio
  • Figure 15.66: Pfizer Inc.: Overall Financials, 2017-2019
  • Figure 15.67: Pfizer Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.68: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
  • Figure 15.69: Pfizer Inc.: Revenue (by Region), 2017-2019
  • Figure 15.70: Pfizer Inc: R&D Expenditure, 2017-2019
  • Figure 15.71: Pfizer Inc.: SWOT Analysis
  • Figure 15.72: Sanofi SA: Overall Product Portfolio
  • Figure 15.73: Sanofi SA: Overall Financials, 2017-2019
  • Figure 15.74: Sanofi SA: Revenue (by Segment), 2017-2019
  • Figure 15.75: Sanofi SA: Revenue (by Region), 2017-2019
  • Figure 15.76: Sanofi SA: R&D Expenditure, 2017-2019
  • Figure 15.77: Sanofi SA: SWOT Analysis
  • Figure 15.78: Teva Pharmaceutical Industries Ltd.: Overall Product Offerings for Global Neurodegenerative Disorder Therapeutics Market
  • Figure 15.79: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
  • Figure 15.80: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
  • Figure 15.81: Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
  • Figure 15.82: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
  • Figure 15.83: UCB Pharma SA: Overall Product Portfolio
  • Figure 15.84: UCB Pharma SA: Overall Financials, 2017-2019
  • Figure 15.85: UCB Pharma SA: Revenue (by Product), 2017-2019
  • Figure 15.86: UCB Pharma SA: Revenue (by Region), 2017-2019
  • Figure 15.87: UCB Pharma SA: R&D Expenditure, 2017-2019
  • Figure 15.88: UCB Pharma SA: SWOT Analysis

List of Tables

  • Table 1: Leading Players in Global Neurodegenerative Disorder Therapeutics Market
  • Table 4.1: Comparison of Drug Development Within and Outside the Central Nervous System
  • Table 4.2: Commercialized Neurodegenerative Disorders Therapeutic Products
  • Table 8.1: Regulatory Scenario Across the World
  • Table 8.2: Expedited Regulatory Designations Around the World
  • Table 8.3: Current Regulatory Development Guidelines for Neurodegenerative Disorders
  • Table 15.1: AbbVie Inc.: Pipeline Product Portfolio
  • Table 15.2: Biogen Inc.: Pipeline Product Portfolio
  • Table 15.3: Bristol Myers Squibb Company: Pipeline Product Portfolio
  • Table 15.4: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
  • Table 15.5: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
  • Table 15.6: F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio
  • Table 15.7: H. Lundbeck A/S Company: Pipeline Product Portfolio
  • Table 15.8: Merck KGaA: Pipeline Product Portfolio
  • Table 15.9: Novartis AG: Pipeline Product Portfolio
  • Table 15.10: Pfizer Plc: Pipeline Product Portfolio
  • Table 15.11: Sanofi SA: Pipeline Product Portfolio
  • Table 15.12: Teva Pharmaceutical Industries Ltd Company: Pipeline Product Portfolio
  • Table 15.13: UCB Pharma SA Company: Pipeline Product Portfolio
目次
Product Code: BHL0960SA

"Global Neurodegenerative Disorder Therapeutics Market to Reach $98.16 Billion by 2030."

Market Report Coverage - Neurodegenerative Disorders Therapeutics

Market Segmentation

  • Indication - Multiple sclerosis, Parkinson's disease, Alzheimer's disease, Spinal Muscular Atrophy, Huntington disease, and other Neurodegenerative disorders
  • Drug Class - Immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and others
  • Route of Administration - Oral, Injectable, Enteral, and Transdermal

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Rest-of-Europe
  • Asia-Pacific - China, Japan, India, South Korea, Australia, Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Rest-of-the-World

Growth Drivers

  • Rising Global Prevalence of Neurodegenerative Disorders
  • The Increase in Number of Geriatric Populations
  • Increasing Research Funding in Neurodegenerative Disorders
  • Rising Awareness about Neurodegenerative Disorders

Market Challenges

  • High Failure Rate of Neurodegenerative Drugs in Clinical Trials
  • Lack of Effective Drugs and Therapies

Market Opportunities

  • Development of Novel therapies for Neurodegenerative Disorders through Gene and Cell Therapies
  • Massive Scope for Adoption of Neurodegenerative Disorders Therapeutics in Emerging Nations

Key Companies Profiled

Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck A/S, Merk KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, and Eisai Co., Ltd.

Key Questions Answered in this Report:

  • What are the various neurodegenerative disorder therapeutics available in the market?
  • What are emerging therapies for the treatment of neurodegenerative disorders?
  • How does the pipeline for global neurodegenerative disorder therapeutics market look like?
  • What is the current market size and future potential of these therapies?
  • What are the major market drivers, challenges, and opportunities in the global neurodegenerative disorder therapeutics market?
  • What mechanisms of action and molecules are being trialed most commonly in pipeline products?
  • Which products will contribute most significantly to the market growth, and which will achieve blockbuster status?
  • How does the clinical landscape look for the neurodegenerative disorder therapeutics market?
  • What is the status of biosimilars in this market?
  • What is the patent landscape of this market? What will be the impact of patent expiry on this market?
  • What is the reimbursement scenario of the available therapeutics in this market?
  • What will be the impact of COVID-19 on this market?
  • What is the mechanism of action of various neurodegenerative disorder therapeutics available in the market?
  • What will be the impact of digitalization on this market?
  • What are the guidelines implemented by different government bodies to regulate the approval of neurodegenerative disorder therapeutics?
  • What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
  • Which leading players currently hold dominant shares in the global neurodegenerative disorder therapeutics market?
  • What are the key strategies incorporated by the players of the global neurodegenerative disorder therapeutics market to sustain the competition and retain their supremacy?
  • What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by product type), and how would it evolve in the forecast period?
  • What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by drug class), and how would it evolve in the forecast period?
  • What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by indication), and how would it evolve in the forecast period?
  • What is the current revenue contribution of the global neurodegenerative disorder therapeutics market (by route of administration), and how would it evolve in the forecast period?
  • Which region is expected to contribute the highest revenue to the global neurodegenerative disorder therapeutics market during the forecast period?

Market Overview

The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030. The market is driven by certain factors, which include the increasing global geriatric population, increasing incidence of chronic diseases including neurodegenerative disorder, and the presence of high unmet clinical needs regarding treatment for immune disorders, and significant external funding for executing R&D exercises.

The market is favored by the development of neurodegenerative disorder therapeutics for several clinical areas such as Multiple sclerosis, Parkinson's disease, Alzheimer's disease, Spinal Muscular Atrophy, Huntington disease, and other neurodegenerative disorders. The increase in the geriatric population and incurable neurodegenerative disorders across the globe are expected to translate into significantly higher demand for neurodegenerative disorder therapeutics market.

Furthermore, the companies are investing huge amounts in research and development of neurodegenerative disorder therapeutics either as a monotherapy or as combination therapy. The clinical trial landscape of different neurodegenerative disorders has been on the rise in recent years, and this will fuel the neurodegenerative disorder therapeutics market in the future.

Within the research report, the market is segmented based on indication, drug class, route of administration, and region. Each of these segments covers the market's snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel neurodegenerative disorder therapeutics. Due to the diverse product portfolio and intense market penetration, Biogen Inc. has been a pioneer in this field and has been a significant competitor in this market.

Several other companies such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, among others, have launched therapies for neurodegenerative disorder, such as Mayzent (siponimod), Ocrevus (ocrelizumab), and Zeposia (ozanimod) respectively, to compete with Biogen Inc.'s Tecfidera (dimethyl fumarate) therapy market dominance.

Based on region, North America holds the largest share of neurodegenerative disorder therapeutics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Technology Definition

  • 1.1 Inclusion and Exclusion Criteria
    • 1.1.1 Inclusions
    • 1.1.2 Exclusions

2 Research Scope

  • 2.1 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Neurodegenerative Disorder Therapeutics: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Neurodegenerative Disorder Therapeutics and Its Clinical Importance
  • 4.2 Neurodegenerative Disorder Therapeutics Development and Commercialization Landscape
  • 4.3 Global Neurodegenerative Disorder Therapeutics Market and Growth Potential, 2019-2030
  • 4.4 Pricing and Reimbursement Scenario
  • 4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
  • 4.6 Impact of COVID-19 on Neurodegenerative Disorder Therapeutics Market

5 Epidemiology of Neurodegenerative Disorder Therapeutics

6 Patent Landscape

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Impact Analysis
  • 7.3 Drivers
    • 7.3.1 Rising Global Prevalence of Neurodegenerative Disorders
    • 7.3.2 The Increase in Number of Geriatric Populations
    • 7.3.3 Increasing Research Funding in Neurodegenerative Disorders
    • 7.3.4 Rising Awareness about Neurodegenerative Disorders
  • 7.4 Restraints
    • 7.4.1 High Failure Rate of Neurodegenerative Drugs in Clinical Trials
    • 7.4.2 Lack of Effective Drugs and Therapies
  • 7.5 Opportunities

8 Industry Insights

  • 8.1 Overview
  • 8.2 Regulatory Scenario
  • 8.3 Legal Requirements and Frameworks in the U.S.
    • 8.3.1 Clinical Trial Authorization
    • 8.3.2 Marketing Authorization
    • 8.3.3 USFDA Guidelines for BLA Submission
    • 8.3.4 Post-Authorization Regulations
  • 8.4 Legal Requirements and Frameworks in Europe
    • 8.4.1 EMA Biologics License Application Process
    • 8.4.2 Centralized Procedure
    • 8.4.3 Decentralized Procedure
    • 8.4.4 Mutual-Recognition Procedure
    • 8.4.5 National Procedure
  • 8.5 Legal Requirements and Frameworks in Asia-Pacific
    • 8.5.1 China
    • 8.5.2 Japan
  • 8.6 Expedited Regulatory Designations Around the World
  • 8.7 Role of Regulatory Bodies and Consortium in Neurodegenerative Disorder Therapeutics
  • 8.8 Regulatory Guidelines
    • 8.8.1 Terminology Applied in Current Regulatory Guidelines for Development of Drugs to Treat Neurodegenerative Disorders
    • 8.8.2 Actionable Recommendations
      • 8.8.2.1 EU:
      • 8.8.2.2 EU:
      • 8.8.2.3 Both Regions:
  • 8.9 Regulatory Challenges
  • 8.1 Reimbursement and Market Access

9 Global Neurodegenerative Disorder Therapeutics Market, by Product Type ($Million), 2019-2030

  • 9.1 Commercialized Therapeutics
    • 9.1.1 Multiple Sclerosis
      • 9.1.1.1 Tecfidera
      • 9.1.1.2 Ocrevus
      • 9.1.1.3 Gilenya
      • 9.1.1.4 Aubagio
      • 9.1.1.5 Interferon (Avonex and Plegridy)
      • 9.1.1.6 Tysabri
      • 9.1.1.7 Rebif
      • 9.1.1.8 Copaxone
      • 9.1.1.9 Betaseron
      • 9.1.1.10 Lemtrada
      • 9.1.1.11 Mavenclad
      • 9.1.1.12 Fampyra
      • 9.1.1.13 Ampyra
      • 9.1.1.14 Mayzent
      • 9.1.1.15 Vumerity
      • 9.1.1.16 Others
    • 9.1.2 Epilepsy
      • 9.1.2.1 Lyrica
      • 9.1.2.2 Vimpat
      • 9.1.2.3 Onfi
      • 9.1.2.4 Keppra
      • 9.1.2.5 Sabril
      • 9.1.2.6 Briviact
      • 9.1.2.7 Fycompa
      • 9.1.2.8 Banzel
      • 9.1.2.9 Others
    • 9.1.3 Alzheimer's Market
      • 9.1.3.1 Ebixa
      • 9.1.3.2 Namenda XR
      • 9.1.3.3 Namzaric
      • 9.1.3.4 Galantamine
      • 9.1.3.5 Others
    • 9.1.4 Parkinson's Disease
      • 9.1.4.1 Azilect
      • 9.1.4.2 Neupro
      • 9.1.4.3 Madopar
      • 9.1.4.4 Duopa
      • 9.1.4.5 Inbrija
      • 9.1.4.6 Others
    • 9.1.5 Spinal Muscular Atrophy (SMA)
      • 9.1.5.1 Spinraza
      • 9.1.5.2 Zolgensma
      • 9.1.5.3 Others
    • 9.1.6 Huntington's Disease
      • 9.1.6.1 Austedo
      • 9.1.6.2 Xenazine
      • 9.1.6.3 Others
  • 9.2 Pipeline Therapeutics
    • 9.2.1 Multiple Sclerosis
      • 9.2.1.1 Zeposia
      • 9.2.1.2 Ponesimod
      • 9.2.1.3 Ofatumumab
      • 9.2.1.4 Ublituximab
      • 9.2.1.5 Ibudilast
      • 9.2.1.6 SAR442168
    • 9.2.2 Alzheimer's Disease
      • 9.2.2.1 Tricaprilin
      • 9.2.2.2 Bryostatin-1
      • 9.2.2.3 AGB101
      • 9.2.2.4 COR388
      • 9.2.2.5 TRx0237
      • 9.2.2.6 Brexpiprazole
      • 9.2.2.7 Semorinemab
      • 9.2.2.8 Aducanumab
    • 9.2.3 Parkinson's Disease
      • 9.2.3.1 Eltoprazine
      • 9.2.3.2 Ongentys
      • 9.2.3.3 IPX-066
      • 9.2.3.4 Xadago
      • 9.2.3.5 Nourianz
      • 9.2.3.6 Opicapone
    • 9.2.4 Huntington's Disease
      • 9.2.4.1 RG6042/IONIS -HTTrx
      • 9.2.4.2 WVE-120101
      • 9.2.4.3 WVE-120102

10 Global Neurodegenerative Disorder Therapeutics Market, by Drug Class ($Million), 2019-2030

  • 10.1 Introduction
  • 10.2 Immunomodulators
  • 10.3 Interferons
  • 10.4 Dopamine Agonists
  • 10.5 Decarboxylase Inhibitors
  • 10.6 Others

11 Global Neurodegenerative Disorder Therapeutics Market, by Indication ($Million), 2019-2030

  • 11.1 Overview
  • 11.2 Multiple Sclerosis
  • 11.3 Epilepsy
  • 11.4 Spinal Muscular Atrophy (SMA)
  • 11.5 Alzheimer's Disease
  • 11.6 Parkinson's Disease
  • 11.7 Huntington's Disease
  • 11.8 Other Neurological Disorders

12 Global Neurodegenerative Disorder Therapeutics Market, by Route of Drug Administration ($Million), 2019-2030

  • 12.1 Introduction
  • 12.2 Oral
  • 12.3 Injectable
  • 12.4 Enteral
  • 12.5 Transdermal
  • 12.6 Others

13 Global Neurodegenerative Disorder Therapeutics Market, by Region ($Million), 2019-2030

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
      • 13.2.1.1 U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.2.2 Canada
      • 13.2.2.1 Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • 13.3 Europe
    • 13.3.1 Germany
      • 13.3.1.1 Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.3.2 U.K.
      • 13.3.2.1 U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.3.3 France
      • 13.3.3.1 France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.3.4 Italy
      • 13.3.4.1 Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.3.5 Spain
      • 13.3.5.1 Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.3.6 Rest-of-Europe
      • 13.3.6.1 RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • 13.4 Asia-Pacific
    • 13.4.1 China
      • 13.4.1.1 China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.4.2 Japan
      • 13.4.2.1 Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.4.3 India
      • 13.4.3.1 India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.4.4 South Korea
      • 13.4.4.1 South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.4.5 Australia
      • 13.4.5.1 Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.4.6 Rest-of-APAC
      • 13.4.6.1 RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • 13.5 Latin America
    • 13.5.1 Brazil
      • 13.5.1.1 Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.5.2 Mexico
      • 13.5.2.1 Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
    • 13.5.3 Rest-of-Latin America
      • 13.5.3.1 RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
  • 13.6 Rest-of-the-World

14 Competitive Landscape

  • 14.1 Key Developments and Strategies
    • 14.1.1 Regulatory and Legal Developments
    • 14.1.2 Partnerships, Alliances, and Business Expansions
    • 14.1.3 M&A Activities
    • 14.1.4 Funding Activities
  • 14.2 Market Share Analysis

15 Company Profiles

  • 15.1 Overview
  • 15.2 AbbVie Inc.
    • 15.2.1 Company Overview
    • 15.2.2 Role of AbbVie Inc. in Global Neurodegenerative Disorder Therapeutics Market
    • 15.2.3 Financials
    • 15.2.4 Key Insights about Financial Health of the Company
    • 15.2.5 SWOT Analysis
  • 15.3 Bayer AG
    • 15.3.1 Company Overview
    • 15.3.2 Role of Bayer AG in Global Neurodegenerative Disorder Therapeutics Market
    • 15.3.3 Financials
    • 15.3.4 Key Insight about Financial Health of the Company
    • 15.3.5 SWOT Analysis
  • 15.4 Biogen Inc.
    • 15.4.1 Company Overview
    • 15.4.2 Role of Biogen Inc. in Global Neurodegenerative Disorder Therapeutics Market
    • 15.4.3 Financials
    • 15.4.4 Key Insights about Financial Health of the Company
    • 15.4.5 SWOT Analysis
  • 15.5 Bristol-Myers Squibb Company
    • 15.5.1 Company Overview
    • 15.5.2 Role of Bristol Myers Squibb Company in Global Neurodegenerative Disorder Therapeutics Market
    • 15.5.3 Financials
    • 15.5.4 Key Insights About Financial Health of the Company
    • 15.5.5 SWOT Analysis
  • 15.6 C. H. Boehringer Sohn AG & Co. KG
    • 15.6.1 Company Overview
    • 15.6.2 Role of C. H. Boehringer Sohn AG & Co. KG in Global Neurodegenerative Disorder Therapeutics Market
    • 15.6.3 Financials
    • 15.6.4 Key Insight about Financial Health of the Company
    • 15.6.5 SWOT Analysis
  • 15.7 Eisai Inc.
    • 15.7.1 Company Overview
    • 15.7.2 Role of Eisai Inc. in Global Neurodegenerative Disorder Therapeutics Market
    • 15.7.3 Financials
    • 15.7.4 Key Insight about Financial Health of the Company
    • 15.7.5 SWOT Analysis
  • 15.8 F. Hoffmann-La Roche Ltd.
    • 15.8.1 Company Overview
    • 15.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Neurodegenerative Disorder Therapeutics Market
    • 15.8.3 Financials
    • 15.8.4 Key Insights About Financial Health of the Company
    • 15.8.5 SWOT Analysis
  • 15.9 GlaxoSmithKline plc
    • 15.9.1 Company Overview
    • 15.9.2 Role of GlaxoSmithKline plc in Global Neurodegenerative Disorder Therapeutics Market
    • 15.9.3 Financials
    • 15.9.4 Key Insights about Financial Health of the Company
    • 15.9.5 SWOT Analysis
  • 15.1 H. Lundbeck A/S
    • 15.10.1 Company Overview
    • 15.10.2 Role of H. Lundbeck A/S in Global Neurodegenerative Disorder Therapeutics Market
    • 15.10.3 Financials
    • 15.10.4 Key Insight about Financial Health of the Company
    • 15.10.5 SWOT Analysis
  • 15.11 Merck KGaA
    • 15.11.1 Company Overview
    • 15.11.2 Role of Merck KGaA in Global Neurodegenerative Disorder Therapeutics Market
    • 15.11.3 Financials
    • 15.11.4 Key Insights About Financial Health of the Company
    • 15.11.5 SWOT Analysis
  • 15.12 Novartis AG
    • 15.12.1 Company Overview
    • 15.12.2 Role of Novartis AG in Global Neurodegenerative Disorder Therapeutics Market
    • 15.12.3 Financials
    • 15.12.4 Key Insights About Financial Health of the Company
    • 15.12.5 SWOT Analysis
  • 15.13 Pfizer Inc.
    • 15.13.1 Company Overview
    • 15.13.2 Role of Pfizer Inc. in Global Neurodegenerative Disorder Therapeutics Market
    • 15.13.3 Financials
    • 15.13.4 Key Insights About Financial Health of the Company
    • 15.13.5 SWOT Analysis
  • 15.14 Sanofi S.A.
    • 15.14.1 Company Overview
    • 15.14.2 Role of Sanofi SA in Global Neurodegenerative Disorder Therapeutics Market
    • 15.14.3 Financials
    • 15.14.4 Key Insights About Financial Health of the Company
    • 15.14.5 SWOT Analysis
  • 15.15 Teva Pharmaceutical Industries Ltd.
    • 15.15.1 Company Overview
    • 15.15.2 Role of Teva Pharmaceutical Industries Ltd. in Global Neurodegenerative Disorder Therapeutics Market
    • 15.15.3 Financials
    • 15.15.4 Key Insight about Financial Health of the Company
    • 15.15.5 SWOT Analysis
  • 15.16 UCB Pharma SA.
    • 15.16.1 Company Overview
    • 15.16.2 Role of UCB Pharma SA in Global Neurodegenerative Disorder Therapeutics Market
    • 15.16.3 Financials
    • 15.16.4 Key Insight about Financial Health of the Company
    • 15.16.5 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.